With a constellation of leading industrial players established on its soil, Belgium continues to increase its market share in the radiopharmacy sector.
The strong growth of nuclear medicine in Belgium is primarily due to the rise of personalized treatments and innovative products. Nearly 5,000 workers are already active in this sector, which combines fundamental research, engineering sciences, life sciences, and logistics.
This growth is certainly most palpable in Liège, with cutting-edge research, world-class infrastructure, and solid industrial partnerships converging to foster innovations in this sector whose mission is to save lives.
With its nuclear medicine department, the Liège University Hospital has been a pioneer in PET imaging since 1996 and, thanks to judicious strategic choices, has continued to invest in cutting-edge equipment. With over 30 years of expertise in radiochemistry, the Giga Cyclotron (a type of particle accelerator that uses magnetic and electric fields to accelerate charged particles such as protons) enables the development of new radiotracers while attracting innovative SMEs internationally.
Today, despite its small size, Belgium is a European radiopharmaceutical giant, with market shares greater than those of Germany, the United Kingdom, and France.
